Detecting Protein Aggregates on Untreated Human Tissue Samples by Atomic Force Microscopy Recognition Imaging  by Creasey, Rhiannon et al.
1660 Biophysical Journal Volume 99 September 2010 1660–1667Detecting Protein Aggregates on Untreated Human Tissue Samples
by Atomic Force Microscopy Recognition ImagingRhiannon Creasey,† Shiwani Sharma,‡ Jamie E. Craig,‡ Christopher T. Gibson,† Andreas Ebner,§
Peter Hinterdorfer,§* and Nicolas H. Voelcker†*
†School of Chemical and Physical Sciences, and ‡School of Medicine, Ophthalmology, Flinders University, Bedford Park, Australia;
and §Institute for Biophysics, Johannes Kepler Universita¨t Linz, Linz, AustriaABSTRACT We apply topography and recognition (TREC) imaging to the analysis of whole, untreated human tissue for
what we believe to be the first time. Pseudoexfoliation syndrome (PEX), a well-known cause of irreversible blindness worldwide,
is characterized by abnormal protein aggregation on the anterior lens capsule of the eye. However, the development of effective
therapies has been hampered by a lack of detailed knowledge of the protein constituents in these pathological deposits and their
distribution. Using both TREC and immunofluorescence, one of the proteins implicated in the PEX pathology—the apolipopro-
tein clusterin—was detected, and differences in its distribution pattern on the surface of untreated human lens capsule tissue in
both PEX and normal control samples were investigated. Our study shows the potential of TREC imaging for the analysis of
whole, untreated human tissue samples.INTRODUCTIONAtomic force microscopy (AFM) (1) is a versatile surface
characterization method, able to provide high-content infor-
mation on a variety of substrates (2). Samples can be imaged
under physiological conditions rendering AFM an ideal
technique for high-resolution characterization of biological
samples in terms of their topography and, independently,
their affinity toward different chemical or biological species
immobilized on the AFM tip (3,4). Traditionally, AFM has
been unable to combine topography mapping and molecular
recognition mapping because the topography could not be
separated reliably from binding events between the probe
and the surface. However, a modification of the AFM tech-
nique has been developed for rapid mapping of receptor
binding sites of biological substrates using simultaneous
topography and recognition (TREC) imaging (5–10).
TREC operation relies on a receptor-functionalized tip
on a magnetic-coated cantilever driven by a magnetic field
(MAC mode). In this technique (6,10), the probe amplitude
is split into lower and upper regions with respect to the
probe’s resting position. These regions contain information
regarding the topography and recognition events image,
correspondingly (7). TREC has been successfully applied
to many biological systems, such as pure proteins (5,8,11–
13), remodeled chromatic structures (15), and protein super-
structures (11). More complicated systems that have made
use of TREC include imaging erythrocyte membranes to
detect cystic fibrosis transmembrane regulators (16),
detection of vascular endothelial-cadherin binding sites in
microvascular endothelial mouse cells (17), and demonstra-
tion of human ergotoxin channel inhibition in embryonicSubmitted February 13, 2010, and accepted for publication June 18, 2010.
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0006-3495/10/09/1660/8 $2.00kidney cell cultures (18). However, TREC imaging has
not yet been demonstrated on unfixed tissues using function-
alized tips (19).
Most biological tissues would require histological prepa-
ration, such as fixation, before imaging studies. Ocular
tissues such as the human cornea and sclera have been
studied by AFM after fixation and mechanical dissociation
of collagen fibrils (20). Cataract has also been studied using
AFM after extensive sample preparation to homogenize
and extract the membrane proteins from the lens (21).
However, as the ocular lens capsule is a relatively smooth
(roughness <50 nm root mean-square) and thin (20–60 mm
(22)) tissue, we conjectured that it might be amenable for
direct AFM imaging without fixation. It is a clear membrane
encapsulating the ocular lens and is mainly comprised of
proteins in the collagen family. Human lens capsule can
undergo pathological changes, which manifest in protein
misfolding, resulting in protein aggregation. This aggrega-
tion is characteristic of Pseudoexfoliation syndrome (PEX)
(23), which is caused by the formation of insoluble protein
aggregates in the anterior segment of the eye and is charac-
terized by deposition of fibrillar proteinaceous material on
the anterior lens capsule (24). One of the main secondary
effects of PEX is blockage of the aqueous outflow mecha-
nism of the eye (25). This can lead to elevation of intraoc-
ular pressure causing loss of vision due to glaucomatous
damage to the optic nerve, the second leading cause of
irreversible blindness worldwide (26–28). Currently, treat-
ment methods are limited to those that alleviate intraocular
pressure associated with glaucoma, but there is no under-
standing of how to deal with the underlying PEX protein
aggregation (29).
Many factors limit the study of PEX using conventional
techniques: there are very small (submicrogram) amounts
of material for analysis (30) and the deposits are not readilydoi: 10.1016/j.bpj.2010.06.044
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knowledge of the protein constituents of PEX deposits is
limited. Presence of some protein constituents has been
demonstrated by immunohistochemistry and, more recently,
by direct mass spectrometry of PEX lens capsule or isolated
PEX material (26,27). These analyses have shown the pres-
ence of apolipoproteins (26,27,31–33), inflammatory (26),
and extracellular matrix proteins (24,26,37) in pathological
PEX deposits. Common genetic variants in the LOXL1 gene,
involved in the formation of elastic fibers in the extracellular
material (28,34), are associated genetically with PEX (34–
36), and LOXL1 protein is present in PEX material (27).
Despite this knowledge, the disease mechanism remains
poorly understood (35,38). Because of limitations in resolu-
tion and environmental control for established antibody
recognition techniques, such as immunofluorescence and
immuno gold labeling SEM, the protein aggregates them-
selves cannot be analyzed in their native environment using
these techniques. Hence we considered TREC imaging as
a suitable technique for this purpose because it can be
used to localize proteins in PEX material deposited on
lens capsule tissue by imaging the fibrillar deposits at
a higher resolution than optically possible, in a physiological
environment, and affording topographical information at the
same time.
The aim of this study was to apply TREC to whole
untreated human tissue. We focused on the apolipoprotein
clusterin on the lens capsule, which is known to be present
and involved in PEX (26,27,31,33). We first examined
binding of clusterin to anti-clusterin antibody by AFM force
spectroscopy. Human lens capsules were then imaged using
in-fluid AFM, followed by TREC imaging using anti-
clusterin antibody functionalized AFM tips. Clusterin was
observed on the normal lens capsule surface in small, local-
ized spots whereas the PEX lens capsules showed signifi-
cantly larger, localized patches of clusterin. These results
were confirmed by immunofluorescence imaging. We postu-
late that the TREC imaging technique, applied with anti-
bodies specific to other known or putative constituents of
PEX deposits will lead to a more complete understanding
of the disease pathology. Such understanding may form
the basis of earlier detection methods and treatments that
directly target protein accumulation instead of the subse-
quent glaucoma and therefore prevent loss of vision or
blindness in the affected patients. TREC imaging may
also be applicable to other types of tissues such as blood
vessels or the retina.MATERIALS AND METHODS
AFM tip modification
AFM probes were functionalized with anti-clusterin antibodies as described
for other antibodies (39). Briefly, AFM probes were amino-functionalized
with 3-aminopropyl triethoxysilane (Sigma-Aldrich, St. Louis, MO) using
a vapor phase deposition method (40). The heterobifunctional cross-linkerNHS-PEG800-aldehyde (prepared as per Ebner et al. (39)) was covalently
bound to the amine groups on the tips for 2 h at a concentration on
6.6 mg/mL in chloroform with 1% (vol/vol) triethylamine. After washing
and drying, the probes were then immersed in phosphate buffered
saline buffer (PBS; 150 mM NaCl, 5 mM NaH2PO4, pH 7.4) containing
0.2 mg/mL of HPLC-purified anti-clusterin antibodies (rabbit anti-CLU
primary antibody; Santa Cruz Biotechnology, Heidelberg, Germany) and
2 mL of sodium cyanoborohydride (NaCNBH3) solution (32 mg NaCNBH3,
50 mL of 100 mM sodium hydroxide in 450 mL MilliQ water) for 2 h.
Subsequently, 5 mL of 1 M ethanolamine-hydrochloride (Sigma-Aldrich)
was added to the solution for 10 min to quench any remaining aldehyde
groups. Finally, the probes were washed and stored in PBS buffer at 4C
for no more than 1 week.Sample preparation for AFM
For force spectroscopy measurements, freshly cleaved mica was incubated
with recombinant human clusterin (human recombinant clusterin; Biomed-
ica Medizinprodukte, Austria; 150 mg/mL in PBS buffer) for 1 h, and then
rinsed 50 times in 500 mL PBS buffer to remove any loose protein. Freshly
prepared clusterin samples were placed into the AFM liquid cell and 600 mL
PBS buffer was added.
Human lens capsules were collected from patients undergoing cataract
surgery, according to the ethical guidelines of the Flinders Clinical Research
Ethics Committee, Flinders Medical Centre, Australia. Samples were stored
in sterile MilliQ water or balanced salt solution (NaCl, KCl, CaCl2  H2O,
MgCl2 6H2O, C2H3NaO2 3H2O, and C6H5Na3O7 2H2O) at 4C until
use. Lens capsules were carefully washed three times in 1 mL MilliQ water
and placed flat on a cleaned glass coverslip. The slide was dried thoroughly
under a gentle stream of nitrogen to immobilize the tissue and then rehy-
drated in theAFMliquid cellwith 600mLPBSbuffer. Interestingly, the tissue
lifted off the surface if dried from PBS buffer and hence the tissue needed to
be either stored in fluid or washed thoroughly with MilliQ water before dry
storage. Lens capsules were stable for reuse when stored carefully in PBS
buffer at 4C for up to 1 week. As the AFM experiments were conducted
in a nonsterile environment, lens capsules were discarded after 1 week.AFM
AFM probes (nominal spring constant 0.03 N/m; MSNL; Veeco, Plainview,
NY) modified with antibody as described above were used for force
spectroscopy measurements as detailed by Riener et al. (41). Briefly, for
each functionalized tip prepared, 1000 force spectroscopy curves at a given
force loading rate were collected on a Pico-SPMAFM (Molecular Imaging,
Santa Clara, CA) using a fluid cell. MATLAB 7.1 (The MathWorks, Natick,
MA) was used for force curve analysis and spring constant determination as
described by Riener et al. (41). Spring constants were determined using
both the Sader (42) and the thermal noise (43,44) methods for Veeco probes,
and were found to be between 0.013 and 0.090 N/m.
For AFM topography and recognition measurements, MAC probes
(Agilent MACLevers Type VI (N9865B); Agilent Technologies, Santa
Clara, CA) with nominal spring constant 0.292 N/m) modified with anti-
body as above were used for imaging. MAC mode images were acquired
using a PicoPlus AFM (Agilent Technologies) fitted with a fluid cell in
PBS buffer at room temperature using similar experimental conditions as
described by Stroh et al. (5) and Ebner et al. (10). TREC measurements
were made in regions of interest of less than 5  5 mm2 and at scanning
speeds of 1 line/s (or slower) using full amplitude feedback (7). A very
low cantilever drive frequency (3–5 kHz) was used for imaging, as cross
talk is minimized due to the extra time for topography signal to decay
before recognition signal is measured (7). For the MAC mode probes, the
thermal noise method was used for calibration and spring constants were
found to be between 0.2 and 0.9 N/m.
The process of blocking verifies probe-ligand specificity, as the interac-
tion between the probe receptor and the surface ligand is interrupted toBiophysical Journal 99(5) 1660–1667
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ments, blocking of the antibody on the probe was done with free clusterin
or blocking of the surface clusterin was done with anti-clusterin antibodies
(150 mg/mL) in PBS buffer. Additional recognition blocking was done by
amplitude adjustment as described by Preiner et al. (7) for TREC imaging.
Images for Fig. 1 were acquired using a Nanoscope IV Multimode SPM
(Veeco) AFM operating in Acoustic AC (AAC) mode. The cantilevers used
were OTR8 probes (0.57 and 0.15 N/m nominal spring constant; Veeco).
Freeware Gwyddion data analysis (http://gwyddion.net/) and Nanoscope
v6 (Veeco) software was used for AFM data and image analysis.
Immunofluorescence
Human lens capsules were collected from patients undergoing cataract
surgery according to the ethical guidelines of the Flinders Clinical Research
Ethics Committee, Flinders Medical Centre, Australia. Samples were stored
in sterile MilliQ water or balance salt solution at 4C until used. Human lens
capsules were carefully cut into pieces and immobilized in wells of cell
culture plate using superfine syringe needles. For immunolabeling of the
ZO-1 protein, the samples were washed three times in PBS, blocked in
150 mL 5% donkey serum for 15 min, hybridized with 150 mL rabbit anti-
ZO-1 primary antibody (1:400 dilution) (Zymed Laboratories) for 1 h, and
thenwith 150mLAlexa Fluor-488 conjugated goat anti-rabbit IgG secondary
antibody (1:1000 dilution) (Molecular Probes) for 1 h. After each incubation
the sampleswerewashed three times inPBS.After labeling, the sampleswere
mounting on glass slides in buffered glycerol. Clusterinwas similarly labeled
with the rabbit anti-CLU primary antibody (1:250 dilution) (Santa Cruz
Biotechnology) without blocking the sampleswith donkey serum. The nega-
tivecontrol samplewas incubatedwith1%donkey serum insteadof a primary
antibody. Imageswere takenon aLeicaSP5ConfocalMicroscopewithLeica
Application software using the Argon laser (excitation 488 nm, emission
525 nm) in z-plane optical sections of 1-mm intervals.RESULTS AND DISCUSSION
Force spectroscopy
Clusterin (apolipoprotein J) was selected as a model protein
for the testing of this system as it has been clearly implicatedFIGURE 1 (A) Three-dimensional representation of an AFM image of
normal lens capsule on glass using AAC mode in MilliQ water. (B)
Three-dimensional representation of an AFM image of PEX lens capsule
on glass using AAC mode in MilliQ water. (C) Two-dimensional represen-
tation of A (scale bar ¼ 2 mm, z-scale ¼ 20 nm). (D) Two-dimensional
representation of B (scale bar ¼ 2 mm, z-scale ¼ 160 nm).
Biophysical Journal 99(5) 1660–1667in the PEX pathology (26,27,31,33), and both the protein
and antibody are readily available commercially. The
NHS-PEG800-aldehyde cross-linker was chosen because it
allows easy and stable binding of (lysine containing)
proteins to amino functionalized tips. This cross-linker has
also been used previously for antibody experiments (39),
and we have followed the published protocol.
To verify the specificity of the antibody-protein interac-
tion, force spectroscopy was carried out using recombinant
human clusterin adsorbed on mica and an anti-clusterin
coated AFM tip. Pull-off forces were between 12 and
85 pN with an average unbinding force of 40 pN. These
values are slightly lower than other reported antibody-
antigen forces (45). However, they are within experimental
variation. After incubation of the tip with clusterin to block
the antibody, the number of unbinding events dropped
from 7% to 2% at 300 nm/s tip velocity, indicating that the
adhesion is occurring primarily due to the antibody-protein
interaction, and validating the specificity of the modified
probe. Force spectroscopy can also be used to determine
the stretched linker length before unbinding. The average
linker length was calculated as 20 nm (54 nm), which is
expected as the theoretical length of the linker combined
with an antibody is 20 nm (5). This information from the
force spectroscopy data is useful for calculation of ampli-
tudes necessary for TREC data collection.AFM imaging
Because lens capsule tissue has not been used previously for
AFM analysis, imaging (using a nonfunctionalized tip) was
carried out to optimize the technique of lens capsule
mounting and to establish the relevant AFM parameters.
Dehydration is often used in protein studies by AFM (46)
and immunofluorescence (47). The surface of the normal
lens capsule was not observed to be affected by dehydration
(Fig. S1 and Fig. S2 in the Supporting Material for nondehy-
drated and rehydrated tissues, respectively). Hence drying
of the lens capsule was used as this tissue adheres strongly
to a clean glass substrate on dehydration. Even after rehy-
dration in MilliQ water for R24 h, the tissue remained
tightly attached to the substrate. AFM imaging with a non-
functionalized tip using tapping mode of the rehydrated lens
capsule tissue in MilliQ water allowed high resolution
surface images of both control and PEX lens capsules
(Fig. 1). The normal lens capsule surface was very soft, and
many of the features were distorted or not resolved (Fig. 1, A
and C). However, the sample topography was mostly
smooth, with some fibers (1–10 nm high and 1–100 nm
wide; Fig. S2 A) seen across the surface. These fiber like
surface features were expected because the lens capsule is
known to be composed predominantly of the fibrous base-
ment membrane proteins collagen IV and laminin. These
fiber proteins are networked with nidogen and perlecan
(22) to form the basement membrane matrix. On the other
FIGURE 2 AFM images of normal lens capsule mounted on a glass slide
using MACmode in PBS. The left panels show topography images whereas
the panels on the right show the corresponding TREC images. (A and B)
Acquired with a tip oscillation amplitude of 22 nm. (C and D) Acquired
with a tip oscillation amplitude of 33 nm. (E and F) Acquired with a tip
oscillation amplitude of 44 nm. These amplitude variations are a method
for confirming antibody specificity. The arrows point out corresponding
topographical (left) and recognition (right). Scale bars ¼ 100 nm.
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B and D) showed thicker and denser fibrous features of up
to 5–55 nm high and 10–60 nm wide and in some cases
many microns long (Fig. S2 B). On both normal and PEX
capsules, granular fibers were occasionally observed,
producing an effect similar to a string-of-pearls. This effect
was pronounced in PEX images, as seen in Fig. 1, B and D.
Some areas of the PEX capsule contained large aggregates
of PEX material that we were unable to image, leading to
a large variability in roughness values. Measurements for
control lens capsules gave root mean-square roughness of
5–50 nm, whereas the PEX capsules were significantly
rougher with values of 20–200 nm root mean-square. Hence,
PEX images were acquired only on the areas of the capsule
that were relatively less rough. PEX deposits are not uni-
formly distributed across the lens capsule and more deposits
are seen in the peripheral area probably due to physical
rubbing of the overlying iris.
EM images (22,48–51) of these tissues are incomparable
in topography to the AFM images due to the completely
different sample preparation and scales; however, they do
confirm the flat nature of the tissue and the presence of a
fibrous protein network. Topography AFM images obtained
using nonfunctionalized tips showed that the lens capsule is
a suitable tissue for TREC imaging, as areas of <50 nm
root-mean square roughness can be found (7).
TREC imaging was applied successfully to both normal
and PEX lens capsules in PBS buffer using anti-clusterin
antibody functionalized AFM tips. PBS buffer has similar
pH and ionic strength as the aqueous humor that bathes
the lens capsule in vivo, and was therefore an ideal fluid
for imaging conditions. Measurements were made in
regions of interest of less than 5 5 mm2 at a scanning speed
of ¼1 line/s to allow for molecular reorientation and
binding. The tip oscillation amplitude was adjusted to allow
the linker to stretch, but not unbind, to dampen the upper
motion of the cantilever oscillation (this amplitude varied
from 10 to 50 nm). As seen in Fig. 2 (right panels), the
clusterin protein was detected on normal lens capsules. In
recognition images (Figs. 2–4, right panels), dark spots
represent amplitude dampening, and these spots correlate
to topographical features in the same region of interest
(Figs. 2–4, left panels). Recognition spots averaged
240 nm2 in area representing small patches across the
scanned regions, but did not seem to follow a specific distri-
bution pattern. When compared to PEX capsule imaging, a
difference in detection was observed; the dark spots corre-
sponding to recognition (Fig. 3, right panels) formed in
larger patches, showing an increased localization of protein.
Furthermore, these patches were observed frequently in-
between large fibers or around the junction of multiple
fibers. The area of recognition spots averaged 1791 nm2,
with a general trend of having significantly larger areas of
recognition than on normal lens capsules (Fig. 5). An inde-
pendent t-test verified the statistical difference in the meanrecognition spot area between normal and PEX capsules
(t(1119) ¼ 2.7, two-tail p < 0.007), confirming the differ-
ences observed visually. However, it is important to note
that to determine clinical significance, one would require
a far larger number of samples (two normal and two PEX
capsules were analyzed) than were used here. This can be
the subject of a future clinical study. Furthermore, these
results only reflect a difference in distribution of clusterin,
and not a defined quantitative difference on the whole tissue.
Clusterin has been implicated in many protein aggrega-
tion diseases, such as Alzheimer’s disease (52,53). Clusterin
is a molecular chaperone, which is expressed in response to
cellular stress and to inhibit apoptosis (53,54). It is downre-
gulated in anterior segment tissues of PEX affected eyes and
is an integral component of PEX deposits. Its presence in
PEX material may be a response to cellular stress or an
attempt by the natural system to clear abnormal aggregation
of other proteins through its chaperone function. However, it
may be a sign of the natural system being overwhelmed or
of inhibition of the chaperone function of clusterin byBiophysical Journal 99(5) 1660–1667
FIGURE 3 AFM images of PEX lens capsule on glass using MAC mode
in PBS. On the left are topography images whereas the right side is the
corresponding recognition images. (A and B) Acquired with a tip oscillation
amplitude of 15 nm. (C and D) Acquired with a tip oscillation amplitude of
30 nm. (E and F) Acquired with a tip oscillation amplitude of 45 nm.
(G and H) Acquired with a tip oscillation amplitude of 60 nm. These
amplitude variations are a method for confirming antibody specificity.
The arrows point out corresponding topographical (left) and recognition
(right) features. Scale bars ¼ 400 nm.
FIGURE 4 AFM images of normal lens capsule mounted on a glass
slide using MAC mode in PBS with injection of anti-clusterin antibody
(150 mg/mL) to block surface-bound clusterin. On the left are topography
images whereas the right side is the corresponding recognition images.
All images are acquired at a tip oscillation amplitude of 44 nm. (A and
B) Acquired before addition of antibody. (C and D) Acquired 30 min after
injection. (E and F) Acquired 50 min after injection. The arrows point out
corresponding topographical (left) and recognition (right) features.
Scale bars ¼ 300 nm.
1664 Creasey et al.another molecule. Due to the enigmatic nature of the
protein, however, its presence and function may actually
be multifaceted including involvement in lipid movement,
matrix stabilization, or other hitherto unknown functions
(54).
Similar topography was observed using TREC imaging
on both normal and PEX capsules as were seen previously
in Fig. 1 using nonfunctionalized tips. Some difference in
features in the topographical images acquired with TREC
may appear broader than those acquired with a nonfunction-
alized tip (7). This may be attributed to the length of theBiophysical Journal 99(5) 1660–1667linker used to immobilize the antibody to the AFM tip, or
to a tip broadening due to magnetic coating. One way of
increasing image resolution is the use of a shorter linker.
However, a shorter, less flexible linker may reduce or
eliminate immunorecognition, depending on the antibody
orientation. Alternatively, fixation has been reported to
enhance TREC image resolution (17,18,55). Fixation was
not attempted here because we were interested in studying
the PEX aggregates in their native state.
Two control methods designed to remove the antibody
binding event confirmed that recognition was specific for
clusterin and not due to a topographical artifact. First, the
introduction of free antibody into the solution, blocking
surface-bound clusterin, resulted in a significant decrease
in recognition as observed by the shrinking dark spots
(right panels) in the TREC images of Fig. 4. This method
of blocking is not ideal because it contaminates the system
(7) and does not allow further TREC measurements on the
same sample. For this reason it was only carried out once.
Second, a more convenient control method was applied
FIGURE 6 Confocal microscopy images of the anterior side of: (A)
normal lens capsule (scale bar ¼ 20 mm) with inset of digital zoom (scale
bar ¼ 500 nm); and (B) PEX lens capsule (scale bar ¼ 20 mm) with inset of
digital zoom (scale bar ¼ 500 nm) immunolabeled with the anti-clusterin
FIGURE 5 Frequency distribution histogram of TREC recognition spots
observed across normal ( ) and PEX ( ) lens capsule samples measured as
a unit of area (nm2).
AFM Recognition Imaging of Human Tissue 1665for every area analyzed. Recognition imaging is based on
the use of the appropriate oscillation amplitude. If the linker
is stretched too little at low oscillation amplitudes or,
alternatively, if the receptor-ligand bond is broken at each
oscillation cycle when using too large amplitudes, no
pronounced and stable recognition events can be observed.
We therefore increased the amplitude (while keeping the
ratio of amplitude setpoint and free amplitude constant) to
values above a threshold value to prove the specificity of
the interactions. Too high amplitudes resulted in a breakage
of the specific antibody-antigen bonds in the upper part
of the oscillation (Fig. 2, E and F, and Fig. 3, G and H)
(7); the disappearance of the recognition spots on increasing
the oscillation amplitude shows clearly the specificity of the
recognition. From force spectroscopy analysis, one would
predict the threshold amplitude for this effect to be ~20 nm,
the stretched length of the linker and the antibody. The
experimentally determined threshold amplitude while
imaging was higher, requiring an amplitude of up to 50 nm
to remove recognition. This discrepancy may occur due to
deformation of the lens capsule surface, contributing to
the break-off length by acting as an additional spring. We
also examined the amplitude error images (Fig. S3) because
these indicate any feedback artifacts (known as topograph-
ical cross talk) that can occur due to inadequate signal
decay. However, by using a frequency lower than the canti-
lever resonant frequency at the surface, topographical cross
talk was minimized by allowing the topography signal to
decay before the recognition signal is detected (7). We are
confident, therefore, that the features seen in the TREC
images are due to recognition events between the antibody
on the tip and the sample.primary antibody and labeling detected with Alex Flour-488 conjugated
anti-rabbit IgG secondary antibody. Image brightness curves adjusted for
fluorescence visibility. Yellow arrows denote the edge of the tissue, and
the cyan arrows denote the area of the image occupied by tissue. In A,
this edge is due to the pinning procedure used during labeling, whereas B
is the edge of the surgical cut of the lens capsule.Immunofluorescence labeling
Immunohistochemical studies carried out by Ovodenko
et al. (26) confirm a significant presence of the clusterinprotein in PEX aggregates on sections of PEX capsule.
Such optical microscopy methods are limited in resolution
and are not able to distinguish individual proteins or fibers
in the PEX aggregates. However, these are established pro-
cedures for confirmation of presence of a protein and poten-
tial distribution patterns. Immunofluorescent labeling was
carried out on whole lens capsules to further confirm the
specificity of the antibody used, while also providing a
technique to compare the TREC results. Initially, clusterin
was detected in fresh normal lens capsules, as it is known
to be present in the lens epithelial cells that remain attached
to the lens side of the capsule after surgery. Propidium
iodide counterstaining showed the nuclei, and clusterin
was observed within the cells in the cytoplasm (Fig. S4).
However, this protocol required permeabilization with
methanol, which is not done in the AFM protocol, and
may cause antibody trapping leading to nonspecific
labeling. Therefore, further experiments were done without
permeabilization.
The negative control samples (without a primary antibody)
did not show significant fluorescence on the anterior side of
the lens capsule suggesting the signal obtained with the
anti-clusterin antibody to be specific. These samples were
run with and without permeabilization, with no difference
seen (R. Creasey, S. Sharma, J. Craig, and N. H. Voelcker,
unpublished). Additional control labeling carried out with
antibody against ZO-1, an intracellular protein, did not detect
this protein on the anterior side of the capsule. Instead ZO-1
was seen on the lens side in the remnants of damaged lens
epithelial cells (Fig. S5).
Clusterin was detected as a nearly homogenous layer
across the anterior surface of the normal lens capsule
(Fig. 6 A). It should be noted that in PEX the pathological
material forms a layer across the lens capsule before it is
clinically recognizable; as these controls come from cataract
patients, there is a chance that the patient will develop PEX,
but was not showing clinical symptoms at the time of lensBiophysical Journal 99(5) 1660–1667
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capsules were used to confirm this clusterin layer across the
normal anterior capsule, verifying that the clusterin is
present in non-PEX cases. Clusterin showed a significantly
stronger immunofluorescence signal on the anterior side of
the PEX lens capsule, indicating higher expression is coin-
cident with PEX deposits (Fig. 6 B). In particular, clusterin
protein aggregates present were more prevalent in PEX
cases. These results confirm that the PEX lens capsules have
a different pattern of spatial clusterin distribution compared
to normal capsules. The immunofluorescence data is consis-
tent with TREC results where only small (<40 nm) areas of
clusterin were present. However, this technique is clearly
insufficient for molecular topographical studies. TREC
images obtained contain 512 points/mm, whereas fluores-
cence images contained only 40 points/mm, and are also
unable to show topography of PEX deposits.
In terms of PEX investigations, a further observation from
these immunofluorescence data is that the clusterin does not
appear to be permeating the lens capsule from the lens
epithelial cells in normal (Fig. S4) or diseased capsules
(R. Creasey, S. Sharma, J. Craig, and N. H. Voelcker, unpub-
lished). It is known to be expressed from these cells; hence
in this circumstance clusterin may be deposited from the
aqueous humor. This may be an important piece of the
PEX pathophysiological puzzle.CONCLUSIONS
To our knowledge, the AFM recognition imaging technique
TREC was used for the first time in this study to detect a
protein on a human tissue sample. No fixation or processing
of the tissue was applied. We investigated the pattern of
apolipoprotein clusterin in the human lens capsule associ-
ated with the preglaucoma condition PEX. After proving
the specificity of clusterin to anti-clusterin antibody binding
by force spectroscopy, the clusterin protein was shown to be
present on the surface of lens capsules using TREC and
immunofluorescence. It was observed by both methods
that clusterin aggregation patterns differed between normal
and PEX lens capsules. This distribution pattern is thought
to occur due to the aggregation of misfolded proteins in
the PEX disease, leading to a chaperone response by the
clusterin protein. Further investigations are warranted to
confirm the pathological implications. We believe, however,
that this study demonstrates successfully the feasibility of
TREC imaging of biological tissues, and may be used to
analyze protein aggregates in a physiological environment.
Investigation of fixed tissue sections may also be condu-
cive to TREC imaging that would expand the scope of this
approach to the study of other diseases such as neurodegen-
erative disorders or cancer. The possibilities of TREC
imaging are far-reaching and go beyond the exploration of
proteins implicated in diseases. For example, this approach
can be applied to the characterization of protein or tissueBiophysical Journal 99(5) 1660–1667interactions with synthetic biomaterials. Likewise, physio-
logical processes such as the formation of new basement
membranes can be explored. These applications deserve
further investigation given our successful proof-of-principle.SUPPORTING MATERIAL
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